Human neutrophil peptides 1, 2 and 3 are biochemical markers for metastatic colorectal cancer

European Journal of Cancer

Volumn 42, Issue 17, 2006, Pages 3057-3064

  Albrethsen, Jakob ^a   Møller, Christian H ^b   Olsen, Jesper ^a   Raskov, Hans ^c   Gammeltoft, Steen ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c Copenhagen Science Pk Symbion ^*  (Denmark)

Author keywords

Colorectal cancer; Diagnosis; HNP 1 3; Protein marker

Indexed keywords

ALPHA DEFENSIN; BIOCHEMICAL MARKER; DEFENSIN 1; DEFENSIN 2; DEFENSIN 3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CLINICAL ARTICLE; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MASS SPECTROMETRY; METASTASIS; PLASMA; PRIORITY JOURNAL; PROGNOSIS;

ADULT; ALPHA-DEFENSINS; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33750588329     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.05.039     Document Type: Article

References (27)

1. Schoen R.E. The case for population-based screening for colorectal cancer. Nat Rev Cancer 2 1 (2002) 65-70
2. Walsh J.M., and Terdiman J.P. Colorectal cancer screening: scientific review. Jama 289 10 (2003) 1288-1296
3. Desch C.E., Benson A.B., Somerfield M.R., et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 23 33 (2005) 8512-8519
4. Duffy M.J., van Dalen A., Haglund C., et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 39 6 (2003) 718-727
5. Duffy M.J. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clin Chem 47 4 (2001) 624-630
6. Albrethsen J., Bogebo R., Gammeltoft S., Olsen J., Winther B., and Raskov H. Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study. BMC Cancer 5 1 (2005) 8
7. Melle C., Ernst G., Schimmel B., et al. Discovery and identification of alpha-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology 129 1 (2005) 66-73
8. Nam M.J., Kee M.K., Kuick R., and Hanash S.M. Identification of defensin alpha6 as a potential biomarker in colon adenocarcinoma. J Biol Chem 280 9 (2005) 8260-8265
9. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 3 9 (2003) 710-720
10. Wehkamp J., Fellermann K., Herrlinger K.R., Bevins C.L., and Stange E.F. Mechanisms of disease: defensins in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2 9 (2005) 406-415
11. Cunliffe R.N. Alpha-defensins in the gastrointestinal tract. Mol Immunol 40 7 (2003) 463-467
12. Cunliffe R.N., Rose F.R., Keyte J., Abberley L., Chan W.C., and Mahida Y.R. Human defensin 5 is stored in precursor form in normal Paneth cells and is expressed by some villous epithelial cells and by metaplastic Paneth cells in the colon in inflammatory bowel disease. Gut 48 2 (2001) 176-185
13. Cunliffe R.N., Kamal M., Rose F.R., James P.D., and Mahida Y.R. Expression of antimicrobial neutrophil defensins in epithelial cells of active inflammatory bowel disease mucosa. J Clin Pathol 55 4 (2002) 298-304
14. Wehkamp J., Schwind B., Herrlinger K.R., et al. Innate immunity and colonic inflammation: enhanced expression of epithelial alpha-defensins. Dig Dis Sci 47 6 (2002) 1349-1355
15. Muller C.A., Markovic-Lipkovski J., Klatt T., et al. Human alpha-defensins HNPs-1, -2, and -3 in renal cell carcinoma: influences on tumor cell proliferation. Am J Pathol 160 4 (2002) 1311-1324
16. Vlahou A., Schellhammer P.F., Mendrinos S., et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 158 4 (2001) 1491-1502
17. Lundy F.T., Orr D.F., Gallagher J.R., et al. Identification and overexpression of human neutrophil alpha-defensins (human neutrophil peptides 1, 2 and 3) in squamous cell carcinomas of the human tongue. Oral Oncol 40 2 (2004) 139-144
18. Mizukawa N., Sugiyama K., Kamio M., et al. Immunohistochemical staining of human alpha-defensin-1 (HNP-1), in the submandibular glands of patients with oral carcinomas. Anticancer Res 20 2B (2000) 1125-1127
19. Li J., Zhao J., Yu X., et al. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin Cancer Res 11 23 (2005) 8312-8320
20. Bateman A., Singh A., Jothy S., Fraser R., Esch F., and Solomon S. The levels and biologic action of the human neutrophil granule peptide HP-1 in lung tumors. Peptides 13 1 (1992) 133-139
21. Escher N., Spies-Weisshart B., Kaatz M., et al. Identification of HNP3 as a tumour marker in CD4+ and CD4- lymphocytes of patients with cutaneous T-cell lymphoma. Eur J Cancer (2005)
22. Mukae H., Iiboshi H., Nakazato M., et al. Raised plasma concentrations of alpha-defensins in patients with idiopathic pulmonary fibrosis. Thorax 57 7 (2002) 623-628
23. Ashitani J., Mukae H., Arimura Y., Sano A., Tokojima M., and Nakazato M. High concentrations of alpha-defensins in plasma and bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. Life Sci 75 9 (2004) 1123-1134
24. Wood W.G. "Matrix effects" in immunoassays. Scand J Clin Lab Invest Suppl 205 (1991) 105-112
25. Morgan C.L., Newman D.J., Burrin J.M., and Price C.P. The matrix effects on kinetic rate constants of antibody-antigen interactions reflect solvent viscosity. J Immunol Methods 217 1-2 (1998) 51-60
26. Buechler K.F., and Nakamura K.K. More on troponin assays and heparin. Clin Chem 47 1 (2001) 144-147
27. Ohannesian L, Streeter AJ, Dekker M. Handbook of pharmaceutical analysis 2001.